Program
Anti-CD137 Agonistic Monoclonal Antibody CTX-471
Its studies are mostly in Carcinoma, Neuroendocrine · Neoplasm Metastasis, led by Compass Therapeutics.
Furthest: phase 2, since Jun 17, 20262 company-led studies, 1 open or runningNext primary completion: Sep 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Compass Therapeutics | 21 open or running | phase 2since Jun 17, 2026 | Mar 13, 2019 | Sep 2028phase 2 · NCT07684170 |
Also a collaborator on its studies: IQVIA Pty.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 13, 2019First study: phase 1 study in Neoplasm MetastasisFirst studyNCT03881488 · 100 enrolled · United States
- Jun 17, 2026Phase 2 study in Neuroendocrine TumorsPhase 2 reachedNCT07684170 · 58 planned · United States
Ahead
- Sep 2028Primary completion: phase 2 study in Neuroendocrine TumorsNCT07684170
TargetBeta
TNFRSF9 →read by rule
“A fully human immunoglobulin G4 (IgG4) agonistic monoclonal antibody targeting CD137 (4-1BB; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule
Other programs on TNFRSF9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-PD-L1/4-1BB Bispecific Antibody LBL-024rule | nanjing-leads-biolabs-co-ltd | phase 3 | 10 |
| acasunlimabrule | Genmab | phase 3 | 6 |
| Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033rule | BeOne Medicines | phase 3 | 3 |
| CD137/Nectin-4 Bispecific-targeting Agent BT7480rule | bicycletx-limited | phase 2 | 2 |
| Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314rule | BioNTech | phase 2 | 2 |
| Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103rule | abl-bio-inc | phase 2 | 2 |
| Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5 | Sino Biopharmaceutical | phase 2 | 2 |
| Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| LM-2417 | Sino Biopharmaceutical | phase 2 | 1 |
| clesitamig | Hoffmann-La Roche | phase 1 | 2 |
| Anti-CD137/PD-L1 Bispecific Antibody FS222 | Sino Biopharmaceutical | phase 1 | 1 |
| Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015rule | medigene-ag | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07684170Neuroendocrine Tumors · United States | 2 | Recruiting | Sep 2028 | 58 |
| NCT03881488Neoplasm Metastasis · United States | 1 | Terminated | May 21, 2025 | 100 |
How it is read
Names in the registry
- “CTX-471”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Neuroendocrine, 1 study
- Neoplasm Metastasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.